open access

Vol 20, No 1 (2013)
Original articles
Published online: 2013-02-07
Get Citation

Percutaneous mitral balloon valvuloplasty beyond 65 years of age

Zbigniew Chmielak, Mariusz Kłopotowski, Marcin Demkow, Marek Konka, Piotr Hoffman, Krzysztof Kukuła, Mariusz Kruk, Adam Witkowski, Witold Rużyłło
DOI: 10.5603/CJ.2013.0008
·
Cardiol J 2013;20(1):44-51.

open access

Vol 20, No 1 (2013)
Original articles
Published online: 2013-02-07

Abstract


Background:
The profile of subjects undergoing percutaneous mitral balloon valvuloplasty (PMBV) in developed countries has shifted toward the elderly. In the group of elderly patients long-term results after PMBV, as well prognostic factors that may improve patient selection for this procedure have not been fully elucidated. Aim of the study was to evaluate the safety and efficacy of PMBV for the treatment of mitral stenosis in patients older than 65.
Methods: The studied group consists of 132 consecutive patients aged > 65, who underwent PMBV. All PMBV procedures were performed by the antegrade transvenous approach using the Inoue balloon system.
Results: Procedural success, defined as mitral valve area ≥ 1.5 cm2 and mitral regurgitation £ 2+, was obtained in 105 (79.5%) patients. Mean follow-up was 6.25 ± 4.33 years. Echo score > 8 and higher mean mitral valve gradient were significant independent predictors of inadequate immediate result. Survival curves showed that for the whole studied group after PMBV the 3-, 5-, and 10-year overall survival rates were significantly better in patients with left atrium diameter £ 5.0 cm before intervention (95.4%, 91.3% and 80.5% vs. 89.6%, 69.5%, and 53.7%, respectively; p = 0.002). Survival free of mitral valve intervention or heart failure ≥ NYHA III was significantly better for patients with good immediate result and mean pulmonary artery pressure after PMBV < 25 mm Hg.
Conclusions:
PMBV is safe and efficacious in elderly patients with symptomatic mitral stenosis. Long-term results are good and related mainly to the quality of the procedure.

Abstract


Background:
The profile of subjects undergoing percutaneous mitral balloon valvuloplasty (PMBV) in developed countries has shifted toward the elderly. In the group of elderly patients long-term results after PMBV, as well prognostic factors that may improve patient selection for this procedure have not been fully elucidated. Aim of the study was to evaluate the safety and efficacy of PMBV for the treatment of mitral stenosis in patients older than 65.
Methods: The studied group consists of 132 consecutive patients aged > 65, who underwent PMBV. All PMBV procedures were performed by the antegrade transvenous approach using the Inoue balloon system.
Results: Procedural success, defined as mitral valve area ≥ 1.5 cm2 and mitral regurgitation £ 2+, was obtained in 105 (79.5%) patients. Mean follow-up was 6.25 ± 4.33 years. Echo score > 8 and higher mean mitral valve gradient were significant independent predictors of inadequate immediate result. Survival curves showed that for the whole studied group after PMBV the 3-, 5-, and 10-year overall survival rates were significantly better in patients with left atrium diameter £ 5.0 cm before intervention (95.4%, 91.3% and 80.5% vs. 89.6%, 69.5%, and 53.7%, respectively; p = 0.002). Survival free of mitral valve intervention or heart failure ≥ NYHA III was significantly better for patients with good immediate result and mean pulmonary artery pressure after PMBV < 25 mm Hg.
Conclusions:
PMBV is safe and efficacious in elderly patients with symptomatic mitral stenosis. Long-term results are good and related mainly to the quality of the procedure.
Get Citation

Keywords

mitral stenosis; elderly; valvuloplasty

About this article
Title

Percutaneous mitral balloon valvuloplasty beyond 65 years of age

Journal

Cardiology Journal

Issue

Vol 20, No 1 (2013)

Pages

44-51

Published online

2013-02-07

DOI

10.5603/CJ.2013.0008

Bibliographic record

Cardiol J 2013;20(1):44-51.

Keywords

mitral stenosis
elderly
valvuloplasty

Authors

Zbigniew Chmielak
Mariusz Kłopotowski
Marcin Demkow
Marek Konka
Piotr Hoffman
Krzysztof Kukuła
Mariusz Kruk
Adam Witkowski
Witold Rużyłło

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl